Pfizer’s PAXLOVID™ receives FDA approval for adult patients at high risk of progression to severe COVID-19
The Pharma Data
MAY 26, 2023
Pfizer’s PAXLOVID™ receives FDA approval for adult patients at high risk of progression to severe COVID-19 Pfizer Inc. 1) “Great advancements have been made in the fight against COVID-19, yet the virus remains a present and unpredictable concern. NYSE: PFE) announced today that the U.S. More than 11.6
Let's personalize your content